<SEC-DOCUMENT>0001193125-14-020544.txt : 20140124
<SEC-HEADER>0001193125-14-020544.hdr.sgml : 20140124
<ACCEPTANCE-DATETIME>20140124171633
ACCESSION NUMBER:		0001193125-14-020544
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140121
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140124
DATE AS OF CHANGE:		20140124

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		14546796

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d663310d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): January&nbsp;21, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2, Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;21, 2014, Amarin Corporation plc issued a press release
titled &#147;Amarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request.&#148; A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated January 21, 2014</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: January&nbsp;24, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">John Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated January 21, 2014</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d663310dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g663310gg1a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Announces FDA Review Division Response </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to ANCHOR SPA Agreement Reinstatement Request </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>&#150; Conference Call Set for 8:00 a.m. ET today &#150; </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- Amarin Plans Appeal to FDA Office Level, No FDA sNDA Action Expected During Appeal - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, January 21, 2014 &#151; Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular health, announced today that the Division of Metabolism and Endocrinology Products (DMEP) within the U.S. Food and Drug Administration (FDA) has notified Amarin in
connection with Amarin&#146;s request for reconsideration of DMEP&#146;s October 2013 decision to rescind the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement that DMEP &#147;does not plan to re-instate the ANCHOR SPA
agreement.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In its communication to Amarin, DMEP stated that information submitted by Amarin supports testing the hypothesis that Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) 4 grams/day versus placebo reduces major adverse cardiovascular events in statin-treated subjects with residually high triglyceride levels, as is being studied in the Vascepa
REDUCE-IT cardiovascular outcomes study. However, DMEP reiterated its position expressed at the October 2013 Vascepa advisory committee meeting that currently available data from studies of other therapies do not support use of drug-induced
reductions in serum triglycerides as a basis for approval of an indication that DMEP views as ostensibly and impliedly an indication to reduce the risk of cardiovascular disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to being able to appeal DMEP&#146;s October 2013 decision to rescind the ANCHOR SPA agreement, FDA protocol requires that DMEP first be given a formal
opportunity for reconsideration. With that step now completed, Amarin plans to appeal the DMEP decision to the FDA Director of the Office of Drug Evaluation II (ODE-II), the next level under FDA dispute resolution guidance. Based on information
available to Amarin, Amarin does not expect a determination on the pending ANCHOR supplemental new drug application (sNDA) while Amarin prepares its appeal or while this appeal is pending. Amarin also plans to continue its efforts toward a positive
determination on the pending ANCHOR sNDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously stated, Amarin recognizes the significant challenge it faces in its efforts to reinstate the
ANCHOR SPA agreement and obtain approval of the ANCHOR sNDA. There can be no assurance that Amarin will be successful in its effort to reinstate the ANCHOR SPA agreement or obtain a label expansion reflecting the ANCHOR clinical trial. There also
can be no assurance that the FDA will not communicate the results of its review of the ANCHOR sNDA prior to the timing expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa remains FDA
approved for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference call today </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Amarin management
team will host a webcast and conference call to provide a company update and discuss the recent FDA action today at 8:00 a.m. ET. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conference call can be heard live via the investor relations section of the company&#146;s website at
<U>www.amarincorp.com</U>, or via telephone by dialing 877-407-9124 within the United States or 201-689-8584 from outside the United States. A replay of the call will be made available for a period of two weeks following the conference call. To hear
a replay of the call, dial 877-660-6853 (inside the United States) or 201-612-7415 (outside the United States). A replay of the call will also be available through the company&#146;s website shortly after the call. For both dial-in numbers please
use conference ID 13574872. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly pure-EPA
omega-3 prescription product in a 1 gram capsule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indications and Usage </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components and should be used with caution in patients with known hypersensitivity to fish and/or
shellfish. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT <U>WWW.VASCEPA.COM</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa is under various stages of development for potential use in indications that have not been approved by the FDA. Nothing in this press release should
be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.
Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl),
Amarin&#146;s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements, including statements about Amarin&#146;s plan to appeal the ANCHOR SPA agreement rescission and Amarin&#146;s expectation about the timing of FDA response to Amarin&#146;s pending ANCHOR sNDA. These
forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: the
risk that Amarin&#146;s interpretation of the applicable legal standards and scientific information related to the ANCHOR SPA agreement rescission may not be determinative or adjudicated in Amarin&#146;s favor or at all; uncertainties associated
generally with research and development, clinical trials and related regulatory </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decisions; the risk that FDA will follow the recommendation of the advisory committee against ANCHOR sNDA approval; the risk that the FDA may communicate the results of its review of the ANCHOR
sNDA prior to the timing expected. A further list and description the risks and uncertainties associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on this forward-looking statement, which speaks only as of the date hereof. Amarin undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of
other information about Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that we communicate with our investors and the public using our company website
(www.amarincorp.com), our investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public
conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we
post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or
these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin contact information: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joseph Bruno </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Amarin Corporation<B> </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908) 719-1315<B>
</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g663310gg1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g663310gg1a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.P$,`P$1``(1`0,1`?_$`.,```("`@(#`0``````
M```````*"0L'"`$&`@,$!0$``@$%`0``````````````!@<``@,$!0@!$```
M!@$"`P,$"P<-"PP#```!`@,$!08'$0@`$@DA,1,R8A0*05%A@>$BHC,U-CAQ
M0B,T%18WD<%2PD-38R1$9&48.?"AL7*"PU24)F87<X.S)46U1B=WMTAH>$DJ
M$0`!`@0"!0<)!`<%!0D````!`@,`$00%(3%!46$2!G&!P2(R$Q3PD:&QX4(S
M-`?1@B,5\6)RPD-$-5*BLH,DDN*$139C<Z.ST^,E%B;_V@`,`P$``A$#$0`_
M`'\SJ\AM.77W==/UAXD2/#Q_,^5\'$B0>/YORO@XD2#TC3M$H``:ZB)O<^Y[
M(\6WG6V$I4X9;T4I4"<<!$/O4DZU&UKIL77#>,,D.?SPR9E&ZU)G/TZORJ:3
M[%^)YF5*PG<N7(Y6#[T6/BD1$S..$I'<D8IQ()$DS*<%EBX2NE^;<J*9)%*A
M)(61@HC,<VO&-1=+U36UY+(DM9E/&4I^>)<HR;833!A+1+EO(Q,JP:2<9)-%
M@6:/X]^W1=LGC58H<BK=RV7*H0P"(&*8!#@76AUIU33J=U221S@R(.HB-TF2
MV@ZDS!Z8_0\?S/E?!Q(\@\?S/E?!Q(D'C^9\KX.)$@\?S/E?!Q(D'C^9\KX.
M)$@\?S/E?!Q(D'C^9\KX.)$@\?S/E?!Q(D'C^9\KX.)$@\?S/E?!Q(D'C^9\
MKX.)$@\?S/E?!Q(D'C^9\KX.)$@\?S/E?!Q(D'C^9\KX.)$@\?S/E?!Q(D'C
M^9\KX.)$@\?S/E?!Q(D'C^9\KX.)$@\?S/E?!Q(D'C^9\KX.)$@\?S/E?!Q(
MD'C^9\KX.)$@\?S/E?!Q(D'C^9\KX.)$@\?S/E?!Q(D'C^9\KX.)$CV>)^#Y
M]/>U\[3OTXD2/0MY?O!Q(D>KB1(.)GA'AQ$AG&K>]F\W+&VT/<=D?&^1JCB:
M\43$%YM=8R1>(I&?J-2F(&#=R+:1FHA=PV1?(BHV\(A#&-HLH0?#4T\,V9;&
MFZVYL4BFR\HK`D,R9RE&ON*W&*!:V_BH29[,/+GBG!R-DF_YEO%HREE.W3E\
MR!?I=W8;9;+)(GDY:9EI`QEW"J[H>5,B9>;D201*FBBF4$TR%*4"AU_;*=NA
MH6Z&E;[EF4E@^Z?>G+;"-J:VHJJI3KBB7`<-<AEY&+'SU8OJ%EW6;-QVW9`G
MRO\`-VTAO'50OIKH%):UX8?J*)X_LIDS!XBZD`9-2%=J"(F*=NB)^U0O'/OU
M*X:%HO)KJ56_1O$S(R"SCYR!R8&&WPK>#7T0I')=^@3EID,#YIC3I$,S:<+3
M>23NSZT%&F6F#BJ)!Q3OI!W9XQ[(YP=W%82HY"(`29#.#CW=5JB$%.<'%,>0
M<>@$Y14$J.0@[^/%=035A'A24B:L!'.FG%M;K;<M\@3BF8.4<<7(]@XAP$SD
M8]D8X`0'N$![^X=>[377VA#7B$2,CG'F1D<XYXD2#CV1GNZ8](*<XY`!$-0[
M0]O[G?Q22`K=/:,4@A64>.H`&NH:#Q5NF>[[THBSW8FO"`!`==!`=._0=>)(
MYQ;[]HY*$`"`AJ`@(#W#QX,1,91<;4'1O-XICGBD+2K`&(5`9P<5[IBD+0HR
M!QCG3^[4.*=X#FBJ8CCCT8B8RCV.=!X\!GE'DP(--.*I$Q25H3B3''%*2%&2
M<3'J5)5V3.#BO=5JBH=;*#BDC=SB>]N>\(^C]P_N_9\2)LCP6\OW@XD2/5Q(
MD'O:^Y[?N>_Q#$A9#U@G+ESSI/;4^CS@:142R;O@R)`O\Q.(M58'-.V^U>8(
M]EGLJ+/51FPEW<8Y=+&5(8BC6+5*;4J@<'_!-!3T2:CB:O$F*=HA!_[60RYB
M>?;`[>ZM;JDVQGYE[M?9Z/-"S/K&?2SK6P3/F,,G8-K2L1MQSA4X>OL6K!$"
M1]5RKCF`91%CC5C-42(-#7B%:-YM(H!HL[],$---!:/TUXL5>@Y25ZB:I"E*
M.T$SZ9<T!7$O#S=L1XAH=4)`Y\CZ?7$;O2EWS3?3TWO8=W`H.'`41*2"D9CB
M4%"E3E\2VUPU8VGF;^(@BNZ@1!*4;"?F\-=IS`&H\;[BVST_$%E?:;^*V=X'
M:)RC1<.WA=OKM_0L;NG20?3*7FBW=KEBA+=7H&UUJ29S5;LT-&V"OS,<L1PP
ME8:89H/XN19+IF%-=J]9."*)G`=#%,''*3U,ME*V<GTJECF)'&'C3+#M,'_[
M0GYX_:X\BN(S-].]K=1M0G6(87Z<&9=Y-`+2E;39+[BK(M$@#5F2:O7J;RMK
M5*=2<665=-XUL1WXK5)0IB*<A2B<!#C?6JTVVX)'B:SN*A2MT)UY2]X#&-95
MU-=3K*FD`L`3F9X88Y`GT0O*MZY+C%!55%;8'E-!9!4Z*R"^8ZFDX053.=-1
M%=(]1`R2Z:B8E,0?C$,&@Z#PPF/I(JL:#C-=OZ9%,OWX%W.-T(64.A(ERY^:
M)].D]U6\7]5O#EYR31Z)+8GM6-KQ^9]SQG8K%&V29C&SY@C)URRIR$:T8(KP
M]A;"L1(12*)%VJQ!UY0$0+BGARHX6>#"E;Z5#`RV@'2=<X);'>J>[H44D$@>
M7EKB5G@<C;1URVVRO46KV6Z6R3:PE7I\#*V:QS+Y0J+**@H1@XE)21=+*"5,
MB#1DU.<W;['%3/B':INE;3,+,@=I]L>O/=Q3=YH$SYH3FE_7'L-M9:7:PVQW
M)LW#-)63:P\V.7Z@Q":B6KQ5*/E_0?S8<G8C),@37\`RAS)>)RB(B'#:3])Z
MAT(7457=S2%3W?1VA`'4<;M4KY2K=4/O?9S1OWLNZ[NXK?B,-/X#Z2N?K'B=
M>^1M'LV8BYEQPTI=674=QY)]X=29BHAU/&J\:^!TZ09`H?0"I@('-IP,W[@V
MV6H]W47#>=`F$[LB2/OF-M07RHN20[3M@MSD93P&LX<LN3$0R$(``B`&`VG+
MVA[H"(Z=NN@<!,$L8ES;G+$^W'&=MS+FZ]5W'.,Z1'GDK%:[/(MXV.:)D((I
M-$C+G*9[*/U.5)JU1`Z[E8P$3*8P@'%VEMU9<ZUNFIA,J.`VZSJ`TF**RK;H
MJ3OEX>6C;$8O2@ZR6%^JBYS_`!5&J\ICJSX;N:I8>H623:.;%<,0R:B;>IY*
M]#14.6/5=/R*MG[4IE"LUC(E$YO$+P2\2<*U_#W=.U0FAS">C>E.7(='(9QJ
MK;=V;FM0:S"9\TXF2#N[?:]H0[^T.P=![O;TX%AG&Y&8CK5SF9NO4^TSU:K#
MF[6&%KLS+05/9/FL6\M4O'Q[AW'UYK)/=6;!S,NDBMTUE?P29E`,;XH#Q<2R
MRY4I[]83,C'4-?-%3XSY(6HW/>L?7792_JD/NQZ4VZ?"4E>6\@XJ`V')V'Y2
M(L@1!FY)=.'FX![),'*T8+Q(RY#"10B:A3B700U8-F^GCG$J2JU5K3A1F`)$
M'5VO9`Y<K\+.V`MLRUS(Y^R=.&&,XP/A[UJUYN9RA7,);:>FME[)N5K@$H:K
MT\N;Z#$R$N$-%NYJ3,F9Q"),2$91C)5<_.X#XA!TU'C.N'TL>M3/C+U6H98!
ME,:]1Q'Z8U5/QF]5K#=,T%K)E(3/[HQ\PC8/+G7OWB;8:^ZNVZ3HI;K,8X\C
M@YY6]1UZJEHKL2B"A""YE9F%AY**BVI`-VJ/'#9/40#F#7C3L<)6.N7X>BND
MW]`(S_OSC8UE\JZ)L/.,=4YB2A(<Z)>N,_;*/6/^G#O(LS#'KRV67;9DJ64:
MM86N9_2@*Y`663>*`DWBZU?8J<E:N[>JG'0B;I5D=7[P#".G&/?/IY?[4QXI
MU*7*89[D_493'),[(KM_%=MJU=QV!Y9ZL<,8GQ*<IB%.&@E,4#%,4>8IB#\8
M%"B77F(8!U`0[PX"&64D3W2E,Y2.<;YPH2WO4_6!Q'/"]6^/K9[D-A+B\V7+
MW2CSHI@FK7MU3(//T=F7'"]&M35>1595>?%LPC9.6K;:UID*=ND^33,0Y@3,
M/.(`)=;.&*"[N)IV:H=^1,C5E/2)XF!BNOU=;T=[4-!#6]($SQ.)D)`C(3QE
M/1$:#+UQ[&DBY;,6&P/*;Y^]6;-F+)CF*J.W+UT[4(BV:M4$:>9==TX64*0B
M92B<QQ`H!J/!L[]&RRP*A=6`W*<]W(9D]O0(UB>-5E80E"=XD#3G/DB52+ZK
MG4;F*S'VQAT(-UYHR300=-&CK-V'8VP&;.$RJHK.*W)E9S#+G(8!Y%4BJ%`?
MC%`>S@6=X:X<:>[K\X!$Y3W<O_$EZ8WXN]W*]T4_5EVI*E_AWO1$;&1O6XHC
M$%XLV,LI=-C.&/\`(5,DU8:UTVVY6K,+88"51*0ZK*1CG-1YTE.10IB&`3$4
M(8#D,)1`>"JC^DK]PITU=NKD.T:^RJ4IZ#[QT[3&HJ>-!1O%BI0`Z,\^;W9Y
M<\;;=/CUG+;!O;W`Q.WJ]8DL>UZ?NB!6N-+1>K]6['4[?;A<`DC2'4@R80PU
MZ>E4E"_D_P`8#I.W'X`#%4$@'TW$OTOO%FH16I<#S:5=8)!)`EG*9P&GT3C*
MMO%]%7O=RZ`G5RZ)S`ST<F,H9C((F`.SM$1#3L]@=!]GL$!]O00'OX62^HKN
MVNV(*GMP("V^R3ZXTBWF[GL_[;HRER.#-CN6MZ0V%><):&.);O0:G(4-&+;M
M7#!P_:7=XS4F@G#JJIHD9\QR*("!@#F+KM+?34]6?]2^ED:R)](C%JJI^EZM
M,V7//T!7J^R("*MZTC/WO-@[:*/TJ-SU@W!_E^4JO_!]._51K=VMBA_%/*1L
MK$N:XF:)"*12%5VNN)&[=+XYC\FAA-C]/:46Y5W<K4>%E.>X,9&1QWY"!]/$
MS[M4:,-@50./:R.7NSQY)[(GO_K.;G?ZE?\`6'_J(Y"_K">7_4R_XH4'\_?!
M_/C\WOK_`*_F7Z3^:_\`UWX6O-X?\7^=X#/R^@_,/!]^/!2GWFCL[V4]>&<;
M;QU7^7^*[H^*WI;DL>UN^V/JSCNZRCB;(\Q1ZQL2W89RAXQC$NVV1\6-<0*4
MF84D8Y%\X91RENRC69STJ)64%NX!1FF7QB&\,3ET,,IK<S4,AU=8RRHD]50)
M(ER#3G&8Y5+:7N!E:QK&7KC!;_J(;@VS<5D>E%OR<G*(?@2$P`!C!H/=X&8W
M1A[?-`/=XRF[/3;W6N%-+D/V1;-P='9IEGF$8\MO5.SW1Z].7"Q=)W>_#5.K
M0TC8;//3LE@Z,8P<)$,EI&4DG:HY&61!HQ9-SJ*&Y^PI>[70.-@WPY15*DM-
M7*F[U1``2DS]./FC"J+Q5-S4:1>X!G.71$$72@S1N#W';V-T?6(N&Q;<7N`C
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M14M&N4%2)J&%H^:J%,!A#G(!1`N@\=3TE12U3;7A0GNEH"E$9&>O7G"0KJ+P
M+I:5,+!Y#[#Y3BQ%]5BZAJFX?:Y8-G>1[`K(93VK%;EI9Y1T*TG8<'3SA3\W
M0(JH8%70T24\2,'E`?"9BV`?8XYU^J%@79[P;G3)E2N'$)$A,\D-GA&["HH!
M2NJFZ,IXY:(:OX74%\>EVD4[)V/DB9HZ()R@'.`"@H'Q=?9#F[.+C4Q4-;N!
M+@]!TQZXN3!0KLR.$5)=YV1NK;L#SMO=I[1XYEL&;^,D8;RJBB!S$+CFT,XI
MY4K(JF0BPIE@KHX.U='`2$\)^4=?B\=0TEX;9O-';%JW4.4DY9`J!2,LB9'/
M.4X3-7;P]2O5@0%2J`,1D-TF7)Y&,V^KX[[C;(.H3CUO:YM6.PSN+,SPAE$'
M+SP8UB]FWI`Q]<'Z8_@2&K5J433,L?04VCU?M[];'U!X<1<[(Z\TD&I;5O`R
M$\)X3T"6$><+71-!<)'!HZ!E(^4^:+4H!*/<<#``CH8!'E$``!U`PCH8-#!V
MAJ'',*W0T0E:<X=:5H=3OMRW1"]/7OS+=[K5-O'2ZP/+N&6<^HQDV*H5A<Q2
MIBR--V[0#]F]RE:GQTA\1A'OFA!;"=0OAJM4G91'0#!P:\(--LJ>O]6D&DI!
M-*2)@J5AELGAME`]?JA:NXH&)[[A,\9:9#9G(\@V17;[Z\84S"F\[=!AO';<
M6E%Q3FV]8[JS<P*^)^1JE(_D=NNX.L=0QW+E1J=53M[%%!T[--.DK"ZY76ZG
MKZ@S[\@@'$`2[(GHV0F[VP**I72'%P*F5'$Z<)Z!*6&R+!'U4,`'I01XZ:B&
MXW-92B/>`"M7!T`?8`1XYV^IX">*7&TX(DG#1IAJ\'@"T)4.U//S0R=V%U,.
M@`'>/OZ?X>%S-2E]T"=^"N$??6R\CCFF]8$VB8C@;C?,EX8Q]D7='FIA5'T[
M(PE-Q4@R9L8]_:JM'+*0ZSQL+!>0*[=("X9-P)X9@(X-JYOI;3L6U2[G<2DM
MN'=;W\<0<TS\PV@P"<8N//M^%8G-`ZTMHRY-?MA5OIL;W[CT\]X>(]R]<7?*
M5^`ER0>3ZVU57(C<,4SYTVMQAG#=(0*Z6:QX^G,P,`\CYJB;AH\36<<3V=UE
M766B;B"<2,)8:LX"++<GZ2N1NDH2)!4C*>.1U@Q;ZXYO]1RI1*?DBA33*QTN
M^5N&M]5FV"R:[63K\^Q1D8IXDHF8Q1\5HX+S%[R'`Q1[2CQR:ZEVCJET=0"'
M$DB'4BI15(2\SV9>7EK$=R$`'O`!T[0U#N'VP]H>(MMMPS<2%':)QD$DYPC[
MZY1J5GL'Y>S^/9Y'0.S^14#F'3_%']3AV_1Y"$+JRD`$)$MD+SCOJL-A.`]L
M0:^K>)$4ZQFU7F3(;D99A4+S%*/*8F);9RG+J'88O,.@^[P9_4M"/_JA<D-^
M8,],YC3`]PD2+JVF>!(Z8M-YF'A+#%25>L,5&3D#,-'4;,P<NQ;243*L'B/@
MNF$C&NTEFCYJY14Y3IJ$,4Q3:"''+]*2P_WC/4<"4JF,#O88SU[8<>ZE[O6W
M@%-Y2.(EJBH`ZJ&#J+MRZBV[_".,$&S3']'S5.MZG$LNQG7XF:(QL:-?:%Y1
M*F2OK2XM4B%.'(FD!2Z<H:==<(ONW'A^E-7,AQL%6]C/#3/.$;>V6J2Y5'AP
ME(2HREHD=$LM4/C^JY[G<N;BNG7+0F6K+.W60P1F6?Q;5;99'[R5F7E'_(,%
M9(2'>R;WF</BU4\PHR0%0QCD:II$,.A0X0OU'M5/2<0@TDD-+Q*4X`RPR&DP
MRN$GGGK<V5DS!EZ]NR?/&1O6>"$#H^9U`"E#6^X2#L``UUR5"A['?Y0\8?`*
M&U<4M(*1NG>F)9X81E\4'O+0\7.MN2(GC(SE,:C**U;;HBJON$P&DD05%%LY
MXF3(4NG,<#Y!KI0(&HAV&$--..E[FD?EU2D#JI;5(:NJ<H3-O=7XUD*4<QY]
M'IE%U>L`"(E,`"`B;F*(`(#J).\!U`=0XXT4E)WED#?24R.D<D=`A:^[)F9X
MP@IE_I[X^ZF'7OZJ^W*[RSNJS1,*1MVQ?>V0&66I>1X*'Q`VA)1TQ$?1Y.">
MMWZS1^W.!CF;*F,F)%"E$7E0WY7#/!%MKF4I<[U:PL'W4]XL8;9"<`51;&[O
M?:IE?;`&/(E$AGEE"L&Y[;%G'9;G:XX$SK7)&D90Q]+%347:F>EC)ALFX])A
M+C1I\B:'Y6K\F0B:[1\W'XIP$IN55(P`T[95T=^M*:VWD%E:>N.701RZ(!*V
ME>M-665)P2K`Z?+RTP\?ZO-UTE-Q,-6]C.\*W*!G^`CBQ^%<JV20$ILU04:F
M(C5+/*OS$`,F0S<`3;:B*DRU(!NUP0WB(OCO@DVIW\XM*0M"SUD@9:S+S\FC
M"&-PUQ,RZUX>LZRQE/'D\N:&^@*G\8`$!#M$=>W4"Z=HZ]^G9PL0_P#B=VI.
MZJ#1;H=;WVL!LA7C"%:@4/6J]X+QM`Q"+AOL7I$Z#E&-:)K(S4RPQ8QD9@JI
M$@.24E&@F277`?%63$2G$0'3@\N*UH^GM,E),C4J!Y)N$#DF`>4#5`O2!*K]
M5.*`*^[P.G!+8Z9<\-(:!Z-IH&FNNF@::^)KKI[>O`)H^Y^[!)W;?=;NZ-V4
MY2PGGZ\8@#Z@V);';=RMJGX[;9U8\E,S5NG-/SGVF[LZ_B;#3T6L,B/AU^CO
M\H5EZVF6*B@HR"X,T_'<E,<!,`\PEUI*/`IG46ULS5U7D++@QTD((D=&.4::
MN:WJE1[E]>`Q2H`9:(T$?;?KJBHHJ39_ZPS^&*!BH-=^%.<HD-S`)2`)LO.5
M4QU#O$1T#C9=\TR"KQ-I5/"26U$\N*4^L\D8J65E4NZJD`Z9SZ8B)ZDJ>5$R
M8]V>8FQ1UBJ#N3W03;:$JV-=SV[UKDBJ9`QV1VHSM<;'T:O6R483:DFN`(@,
MLY;L$DP5.IS%`>4PX853M-KN-8[;O"(!DI#<RE0$^M,8"6>F!VZ550U5^!:;
MJ5%6&>)G@)"<S.)-,#;3K5A_'%(QG"]-/K8U)C5H1K'K!3-^5#I];7DR)@K*
MR;"L53,\5!02,Q*'6<^`V2(4@JZ")C=O&BN-U\:^JI>KK0HJUM.$RT8]WC*-
MY04YI:9-/X:I)'O$@8Z<)_;RQ//TX,4*UEMD2Z2V*]\F&)MTK&5).H;R=QC_
M`#F::C6B1)@EII[)*_7J&AE$W3@S158#H.3\G+IR]O`#>G1\-+C#J09A322E
M(GL(2?0.4P0V\$U*EJ0M(*1@HSRTCIQ/1"?OK4G3N#!>Y"`WR8[BB(8SW.//
MR)D\K1HFBVKN<82+*<THL*!].3)-?9"Z,<2`!Y!FMJ/,H`"X?IE?N_I#9*@@
M.I3,.$X[L\!++9GHA?<<VO<<%:W/K+ENRV$DSV=,02=-O>S:>GSO(P_N:KQW
M#F&JLU^0<EU]!R=(EKQ98SI,+K"+$*!B'638#Z:T*8OQ7C5,P=O#$XHL+%YM
M2K8ZK>(05)7+&8!($M&,#-@K56JM2]F"0",L\,\3T:XM_*#>JKD^DU#(U&EV
ML_3;Y682X56:9G\1M*UZQ1S>4B7R1@#0/':.2B)1^,0VI1#4!XY'J&W*=Q5.
MX"*E.!2=!&</1!0ZC?;,Q';S!S(J!W:IJA[>H<A@[N+-*X7%!2A(I6,(L/`N
M-'&4DJA13U??!=/W);">J'@;([!)_1\P[Q<^4.92.BDMX#67KL6T1DVZ:H@F
M#R'?F2=(&[RK(E$.T`X:7&-6];;S;[@T9J0PE<LL,)B>T83@3L+**FW55,H8
M;V>>,L^:$3MRNWZ^;4=P>7-NE^(I'7C"][F:>]>)I@B9X2*=IK5RQL#)`<I4
M9^),A(H*:C\X&A@$.'K;JIJ\69%0E0++Z,=.Z2,MN/)C"XKF%6^I6F6(5.>6
M6CDT19X]#[J%QN^/IX4C(MWGFA,I8'8J8NSXX?/`451EZ+"I+M+T_.?11)G;
M:HBA(F4/V"L"X"(B77CF?B^PNVN]>&")AU0*!E-1EO)'(29<H$-SARZ)>M)>
M/;`RV#*?(/5&I/248O\`J$[]-VO6%NK-<^.HV4D=HNQB,?@*S>.Q52'?H=ZR
M#%E4$AF[JV/B"43@703/'9>8>,SB%U-IM#/#['Q<%O*R)42"4D?JJ)`Q,PF<
M8]M"[A6FY/B6[,)3G(Y9\F.0()(T0AKU.?[1K?,/_P!JLU!]W_;"0'7CHOA9
M4K#;VCH0GU0JN)U;UV=)TF?I,/M>JA?V3[#_`/([-?\`TM=XY[^J'_5KGW>F
M&APCA94F)],[YIHVW/#.3\[9,D4XJAXEI-AO5I>&,`'+&5^.7?':M^;RWT@H
MF5NW(`")UE2A[/`)04#]?<4LLC\=:I`;-)YA,P2NNEFG54N@!($QCGJ\\0#=
M#/;E/;@('=%U3]U=7;2N4NI'*SK*K5.Q(>EIU#::V5<P==I:`.#+F"*M;%,A
M#I"4@*L&3<=``P\&/%E2;<MFTT:YM4B4DD?VS)4MA029YXQJ+<V*_O*^I24J
M=!&[F``-TD'3O2U90C;U:MA<WTZ-[>3<#G266QQ).AR#@J=60$A)?$]F<.%H
M-N14OX,[VI/"KQ+@-1."K,#CJ4Y=7MP9?VKO8FW42#^"%IG/`#/SRPVPJN(J
M+\OK%[DRDG/+:(:X]5.ZD*=^QO/].O*4T)[=BEI)WC`#Z2<G76FL:.'0N+-1
M&8+E-JO1)5V+IJF!AT8/!*4`!+A3_5#AE%'5?FM+CO=H2E+49SUX'#5!GP7>
M._8\&]ANZ9X\G3RSPAR[M]K^[VN%.A:S3!]:9+(R@_A(7URIN`0^P1WS#J,Q
MGMIR:=FAH['9N?FUUU^-W:<._P"CQWO%G]40O>.\66^3IA<OH=94LV%.I=@?
M)=.PCDG<38ZW%9/-'8FQ(6&/?+%^4,=S\<Y<1);`_C(@R,.W<F<N`573_`IF
MY1$V@<,+CVD36<+%I;K;0`!WEF0S&PXP+<-.J:N:%I0I<L9#GAJ7>MZT_.[?
M5+%BVO\`3[SAB[<$C&G,T8[FY"*J<!7#NB*ILYI:#KQ)21MK8BA>9(&KI%JL
M<O(9<![.%'9/IDNY%+PKJ?<4C(3)D,9:,3*#BJXN\*VZ?#K"PJ6)]G/"P&Q?
MIT;G>M+N`RA;HW..'X>V3=FE+_FRTWFTD>7QN:R3"CF0L3/%D<DG,34:Y>+&
M20.BJFV;@*::BB0"419M^XBIN#K0S3H;4MU*9#0,M)$Y;.2!"UVTWNI6^ZN2
MG#,B4Y8Z)D$RTRY8LG>G1L)Q5TXML%-VV8K?R-C:Q#Z2LUTO$TV09SF0KY/"
MG^7;3*M6IA09@L1LBW:MBB8K=FW23$QS`)QYUOEXJ;_7_F#AW1/!(Q$M4S+G
M/HAHT%M3;FTM)."=D1R>L\_V/V<O_4#"'_N5"<$/`'_53!U[WJC"XF'_`,-4
M*UI'KBMFVO\`VD]NO_KQA_\`]Q8#CI:X_(5?_=J_PF$G1_/L?M#UB+IU7YP?
MN_KEXXS/8<Y4]$="CX:N4PI#L@T-ZT]U*B]W_D&@43`.@_&9X3[0'V!#ACW?
M#@"W2RWU3V]=R!2WS3Q35*!PU?<;^R)6NKWTB\1]47"S6,>N(Z@[B<=M7BV%
M\RA&IN7,:H8JSI6C6H$S)N)"A6)X4GI*9!!9HL`.$-#`8AQ_AKBRMX;K$I8F
M:!T`+1,@:#O"6F0E*6,;6]6BGO-*H2"'4F<Y3G@1+1I,XJX\TX8SAL_SO8\3
M95@YO%>;,/6MF+E%JX.VE(>:B%T7T!:ZO--%`*Z8NP\%['234PIF*)3%Y1U+
MQT_;'K7>J!-13E+B748IS`WA*<]D]4)]]A^TU*@Z%"1,M$Y8RBPAZ!_71B]\
M]<BMJNYJ78PN[VFUU-&LV5RJ9NRW%UN$:E%].H`*";=AD6+:IE4DF0&Y7I3B
MZ;ET\4A4#QUP0]9*@U=&"JBG/*6[_NGT<F3/X9OC5?1AEV27\L\_++VQ^CMZ
M%=QZTIOF4'44VVQ7&21A,':F&F+2II_<$1$?>XQ[B)_3RA6<"NJ7AJD74^F4
M5T22B^U0.?=D^<-&&=_Y/[_^<X`Y8[OZO1!/[GW>B(!>H/0L:3&Y.RR]GP1U
M?[Y*.*_3R*6?9W>[Y$84731@R()LX&'K]YAF*$NT2*`21BM"BHZ$1,8PZCP8
M6>H?;MZ4(?MJ$S5@Z@*<S.9W%<V.4:&X,,+J2MP5LY#X:@$Y#(;PY\,XCMM%
M*V\5J-F9NPX!]8QK4'`1[VP3TPKD'*!(J&AHMJL\E)%\_<W)5JV8,&2)U5C"
MH'(F41]CC:-U=:IU%.V]9U%Y01+NY9XZ&]DLQ&!_I64K<0:X;B25%2I@#_:.
M,0P;*\9,]Y&ZW.>[V2V_]57</MJJ,@^QQM=MF'LDS,UERM+QRZ`JM+CF%]8X
M>80<)5Y^HJ+&/$R)%9(R9U!Y.TNN]8;-:T66F5:VZTI!7O),CI5(=V<#J,]6
M,:&W,BX5ZJS_`%"J0$]8''+`9^6R)M8S!V*FG@/'&RCUA1-TF(<Y%LYY$=B!
M"Z@)A,WRBF1<W*81`H!J(^[P$NW$*&%19SL#'_MP1-6UH'L7(<JT_P#J0RML
M^QU6\9;>,=5^KL<X140]CUK0G!;C+7-7+,5<<V=RK*/*]<IF?DI>2*\AUG`I
M`V,Y5(W(4"%$2@'`E<7@_4K42R<A-M.Z@R&8$AYY""6B:;88`3WDYGXAFOG,
MSAJQRC'W45V?5???LXS=MDLB+8KR^5-XI1Y=RF)_S:R3"D/*T2PI'!1,R7H%
M@;I`H.H`*!SE'L$0X]L5SJ+;=6ZA,TLI.)_5F)\NOFC'N]+3UE*6W)%9.&TR
M,HI_LDX[NV'\@7C%61X)Y5,@XZM$Q3+G77R9D74388-Z9A),U2B'*HF+A'F3
M,`B51(Q#`(@(#QUQ0W2BK*=NJ9<2ML@3(A"U]/44M:I"DE)!P]</V^JE=0A+
M+&`K;L,R)/IJY"V[`K:,0$?O`.]G<)3KXQGD0S$X%\?_`(>65P9(`YC'!D]1
M[`*3L0?U,LB**\*O+*?P'IY2P/MAK<$W5-50]V^O\;'/,ZSLURT3ANERZ2;-
M'2YSEY4&KE8PZZEY4D%%3"(AJ'*!2B/"PHI.ND#2M/IE!<H'N7/U4F>R>(A8
M#U6!^G*[6]Y<DF8IR2.^_+;XH%'XGAO(R!<EY?-T5T#W`X8/U&7.JH6DXDTH
M')E]D#G"8"F:@GL*6.?JB(R/6X-B*L1;L3=0:C0YRQ=E:QV$<YJLD`,FWG6(
M*.L:6I^8!-R!(1I'$4<_*&IFZ`".I@U*OI7?%.TKMA>5^,A6\V-<C,@'EQYX
MT7&-N`_&93,R,^8?H]<+A]/?<7NKI+S,.S7:\=P[FNHA6ZYMOD&""R@.HA_.
M6!JFC<XLI0YF[YA5GTHS=+?%(6.=*J:@9(NC"XKIK:M;%[N)2WX1)7B,UD=G
M">,SR3$X&.':RM0]X!L'=<&6L9X>;EBUHV?;;J3M`VU84VT8[9IM:KAVB0=0
M07(04SR\JT0\6PV%T!A$QWMAGEW+U41$?CKB`=@!QR]<[BY=+B_4K'76YO$:
M@3,#DAQV]EMFA#:?B`F>N<\8J8NIF8%>HOOE.0><AMU6:1*(#[`W&2*`_JD$
M/>XZVX8!7;*(-XA+*2=G5$(GB,@7)8/:GTP^WZJ&8`Z4#`!'0?ZQV:@[M>]2
MNB'][CGSZG*2KBIQ8(W9#'SPT>$%)_)TITSC73UD'<M<,K6;!_2YP/CO*&=I
MZ]RD%GS=7C7!\8ZG,C.L%U*8:*1%/:H-F+@D=^=+PBCM5=0030(W0$X&!4-<
MG@RTL!ISB*X/HIFD`I;*S@2>K/">G#+7%'$ES<?=;M-$"IU!$P`<Y3Q.P8X;
M)QG*I=:O<=CBIU6AU7H(=1."JE-@(>J5B'90C,&D7`UY@A%13!LFC4C`5)FR
M:D(74=1`-1'4>,97"E'6.NO.7JAWEDDS*\2<3H,O3&S1>#2M!A#2I!(&G5L1
M$+_6[S?G;J@8<HTD;HZ;\\$90P/*S-@C<OVVG+R]?:8T>,55[W7+&WBZRT=A
M&G_)[5\W7$^C15L<1`2G/J4\#4])PY7*;>N-.ZRZ-U*4DSWYB1R`Q$QYH&.(
ME*NM.D-,'?2J9.,Y2.M(R.>N%:]LFX>^;5,_8FW(XJD1:77$MPBK=#%2.4K2
M31:*'3E8"0YBG\:+L4*LLS6`2B`D7$>4>4`X;-ZM#%XI5-.`*WD'#7@=,`=+
M5.6RL0E,TR6F>.T1<)[3=S..-X>W;$^Y+%<FC(TS*]0CK(S226!=6%DU2BE/
MUF1_!IG2EJS-IKLG!3%*/.CKH`"&O)ESHWK?<%6ZI&ZXF8QTRR.K$0_*=YFL
M1WM*H+;GF/;*%&?7*BB:M[`M`U_VCSQ_W7CGAN_1Q"DIK)B4ATP`<>J"6D!6
M&!]<0@>K1-@7ZQ&W,QA`!:U3-#@H"/>8,9SJ(A^HKP7_`%+*7>$^H05(()]7
M3&AX.4Z+HDLRW2)*_9T\\Y0Y)ZP]TRE=_&T5?(V-:]Z=N5VTMIJZX[39D`9*
MZ4KT<'%YQP71=$%W$DT:D?QQ3@<2O6@$(`>.;5*_3Z^?EU<SX@I2PX0)F<@<
M@<M(PY90<\46Q^LHEI94DO3G*6)2,3YOMBMZVJ;F\N[-,^X]W'X2FG,!D7&4
MR#]%N<IP9SL/S@G9:98F9DS@XA[#'%5:.4SE$4Q-SET4(40Z9OM!:KO:7*>I
M:"UJ20E6&>PYB%A0W%^U5Z5MXM;WD8MT]BF\O%6_7;#C/<QB5ZF,+>(HA+!7
M3K%5DJ+>6":!+91ID`(F)9&O22HD`PE`%VYDUB_$4*/')5WLM38*Q=#5)*9'
M>$Y8I5B#@3GZ(=-NN"+E3)J$D;ZIX:I81%MZSR.G1]SF(]P7_"(C[V2H01X(
M.`B$<44Y5D=[U1K^)SNV5Y*NTH2&TY^H16S[8?B;D]NG-V:YZPZ0/=,?(U?*
M4H:=XB(\=+73\.WU2EX`MJ_PF$K0(4Y<&0@3(4)^<1=/*!^&]P!'F_4#37[O
ML<<9S'71[ZBF7-G'0DB&E3UF%'MCP_\`]4'4L'V`P,W#V?88X3'_``<,F[@C
MZ?VX_K+_`/,<@2HC_P#IJD:3/_`B&X]`T#4`'01TU]C74-?U.%L6R4S.@8<L
M&#?X9(5GG*(-.M9T;Z%U/L0FL-13AZ9NRQC#NE<39!62.BVM+)`JCU;%]V42
M6025@;`X*4C5XH!U8MSHH75,5""8<'\65O#[X2LGPRE#>V3(FH<V8YQCF.W^
MQM79!5+\0`RVX&0^SS916/6.MYMVEYT>UFSQMKPGGS!UT1.Y;&,M#6^CW*ON
M47C"1:JIF.40(J1-9JX3%1J\;F`Y0.F<0'IENKI.)+.5]5=,H'K#$>G'T0IW
M$5EDJ0X0I*@1@?5A#AGJ\.[[)6^[J[;AMQN6XZ-;9(EMC-*J%RD(0GH\;8Y2
MB3^/JL-L!ARIHQSJQ>@`NJV2#P$U#&Y/BZ<)_CZV4]IX7I*&F^"BI,N<.*T\
ML'7"UQ=NE>]4/?$4T1+3/\,2\R9P]-_)_?\`\YPG??YNB#W>'=^CGREYXQ-G
M7.&,MN&*<@9OS-:4*3B[&->5M-UM3AC(2:,)"ME$4%71V,2S?R3D17<$*4B*
M*AQ$W=Q;IV5556*=#<U'23('#HBIYQMIKO%"9$(B];/UD"I[K<3VG:'L62N\
M=C6Y"K%9>SG,L'5=?W:I`F"QJ=CR(25"=B8F>43`C]Z^(V7=-^=N1$I3F4%T
M\(\#*IZM%RKW*8H`ZJ=[(Z\<],H`[YQ$\XT:6E9D5&1.&7E+7&Z70;ZUO36V
MW;$L5[6\V9`6VZ9.QK(V)M/K66GVE[7LD35KL[^53MD--U&&G.=1TB\0:K)2
M!6ZZ1D2E*)DR@/&FXYX>N=7?5U='W+C6[B`M(D$C:1RQG\,W`4U'X9Y$E%1T
M:^F'+X^4;3#!C*1K@KF/D6C:08/$^8$G+)Z@1PS<)E4`#&3<MU0.01#L[-0U
M#A7P7Q]0!H'>(CVCJ(:F,(]NIN4`YA'B1(TQW=]07:!L5:U!?=7FF&Q/_P`0
M!F@I;9_!6V?=V<*\FT--I1[.JP,ZOSL0?H@<%2I\PJ`!1'MXR:6TUUW=[B@W
M2ZCKF9`&Z#+,[2(L5%4W2)"W!,*5+GBL0ZTFZ3`>]3J$9@W";9ZS9H_&]HC:
MA%*3<O`N8-:^66L100\I?T(=-KZ1&-)[T9N4@NP([6\'G5(4QA`.E^#Z4V>P
M(9N"Z8N3_M#2<!S93TPI^(U.UEU*V6SN<@U8^?'#1KC5S9%NNR=L8W.XGW/X
MS;OE[!C6P%<R$`X3E&D?<JC)I_DZVT^75;("<S6P0JJB8&,50B3@J2W((IAQ
MMN([?;>(:!=`#3=^E)D9B<_-&FH':B@KTO,,K#04,!JY)RA_*5]:'Z;]HVM7
MJ^-7^4:MFDU'GVL3MVF*+,JW=_:WT:O'LF4=:(MJ\HSB(1?NR'.^._1Y$"B8
M4@/^#X0;'`=TIZ\-I+'=A8*E!0R!GEGCLF(9IXHI'*)P%EP.*1*6@X:YY>:(
M;/5N.KYM'V48FSGM^W=W)_B%:X92>YAJF2I"M66<ITR:8AHN'FJR_4K,/+RL
M7-L7,6"Z1U6X-W**HZ'*<O*8K^H%D=K7:>KH@RI+3000E0GD/LC4\+7--*E8
M=;6A"R)3RPP`\V4LI8PYKNIP-BOJ([+\CX:=/F,]0-PV)ROJ59O152%9.IF.
M0GL<WB/3>M2/6AF$J1H\((IIKD*`E$"B(\*FT5]1P_?D5TR-UP3Y,)C;AZ90
M<UE,Q<*56`.\DRY9&%#_`%7SID6^N;JMQ^YS/E1=Q4IM0M5KVXT2/F6@IE4S
M651:.R/8V:3A(Q5"UBL@FV;G*/X,\GJ0PB4>&O\`4+C&GN5$U149&X\=Y7)G
M+G,N:<!G"MA\/5KJJ@8MX#9[/7A#?.[;?WM#V'Q-3G=V6;:]AUA>G,PSI(S<
M;9)1>S/(!JV>RS2.;UJ$EU/'9H/$A$%`3`><.WOT5-#;;E<'5HI&T%H;H*BH
M`Y:9RRV095=PIJ1D[O+@-9Z8J-]X.6ZEFW=GN7S)2S/_`,T,IYUR??*H:6;^
MBRBM;LMME).&7D&915]$<+1ZZ9Q3U$2\V@Z#V<=76)P6VU4S#JJ85/=`$;PR
MD(1=UIZBHJUOH!4GU8^WHAI;HK=<[9ETY>F!=<7Y3=W&P9_JV7\@VVGXB@:^
M]%;(;>[-XE2"6C+0J0M>C(QB[8JDD57:R2K<I=4TEA,`<*/BWA"NO5_+S9IR
MPJ4Y*&$CJEF1[8.K#?Q;;1N+;ZR<!R_I]D?5T0>L_M`JVY#?/N1ZA^1F^,=Q
MFYNW5Z>@,MSD!.S-&A\:0S=1%IB&NOX2.FY:JH0BQD3E2.DFT=MT$C"8%"`4
M;/&G#CC3%'36="#2--26`H8JEIF1C.,SAVZM/UBJFM1*J7AEY_/AYI0^?6+-
M#W&L5ZXUB31FJY:8*+LE=F&WB%:S$'-L$)*(DVX.$TUBH2#!PFJ3G*4P%.&H
M`.H<*!+*V2IJIW@Z%JP!)D-XR',(-BXDG>#>!C73==O0VM[-*="6S=?EBNXH
MI]TEW53@7EBB[#,-+!+EC%I!U#%9UV$G%52GC2&.8%4P2.3XNHB.G&?16ZLN
M#X:M8)J$XF:I2$\P5$8SEEC%BHJ4,LJ4M&8(&F*EWJ!/-N<[O4W&6+:`66?[
M<+%DJ5L.,U35Z6B601\V1O)RK>%C9!LU?LZXA/.'1(]-1)(Q&@$#D*```=6<
M*.5*+2BEKUT_CTIQFH$X;825XIZBIK%JIVSN3,L!.7VQ.GZNGUFZ#L+D;WMC
MW63,[7MN>1YL+C1;\>)FYJ(Q#>/`%K/MIR.CVKV4:5*WMFZ"AE&B"OH\@D91
M0FBIS%7OU%X4:OB!7VHTYJT`[P"A,[-`GJ).F"CA6XU-O;\/43`/H.OU^@Z(
M[)ZSEU&-I&^Q[M)J6U+)Y,PIXH4R?/76QP%?L\?`QQK@G4F$/%(+6.'A'3^0
M-^1%53^"D=(B0AJ<#=G%CZ:V^NM=(_4/EA.^0D@J$\,#E,15QG5JK&TL,IWC
MCCK/Z.2(L.AWNDQ#LPZD6%L[Y^?R]6Q?&1&0*I/6PM?E)1M5EKG5GL)&3DFT
MCT',B:(:/EB`Y.@DJJF0W,!1`!X+N/&/&\/^#IBTIY202$$3T9[-L:'A\5=L
MN"%5"2E"I`'V1:.[;MTF`=WN-RYBVW9-B,LXU4FI6LIVF#9S;1@>=A5&WY4C
M_19Z+B)'TAF9X4IA\("&*;L$P`(\<UU5!5VY3;#B2@RG(RRUS!.J'"A7B'<-
M*>B*[?UDOIEDV4[KAW$8NKWY/VZ[IYJ4G6K6)9BG$T',JG\<N=1(5H0B3"-L
M>HR\8B0OA@F=RF7YOA]_3?B.BNEO-%<7IU",IF<]1'3M$*SBBQ.L.A5*GJ3]
MLMLM&F4HPMT)NKX;IDY[EJYE5W/RNTW-1V+?)</%-G,@YH-L8_Q>$RE`Q1U2
M"KZ&V4,WF$&Q/&>LN02@=1`A1R^-.%:+B.V!^A=8->T3/>5(R!R(VB4N:+?#
M5PJ[>]X9\GNQHY<CY:)C3$^/7ZZQ_3MW7=.*[X"VW;@H[,.3L@WG&+UC`U>J
M7IJ6&AZU:&=CEY6>?6&LP[)BDU:,N04@.=855"@!=-1`!X!X:NE+Q`R]7EMI
MILJ`.\#,RP``GHQ,X+^(;HFKH`Q2]9[?QY)'ID(1QP_=F^.,O8IR*\:/'S*@
M9+H=X>-$6RZBCII5[3%3KQ%LF9(`,X5;,C$('9J?3AX7E\U%+54@J&NLE2<]
M8EJVPMJ1FKI:Q+JFSN[P.6V+0H_K''1\-4D+8INM:%?.8HLD-,3QSE%6Y-G0
M-_$&'78EIX1J<H1<O@E_C0H&5T$%.7XW'-">#[PFI[A*&2B?;WTR..>N6O"<
M-Y=^I`P3/1"INQGK0;?JEUQ-R^_/-,':\>X,W-04_CZ*E0B5YB1QM#(*5%*I
M62[Q$,B\=NFSYA2B@]!@#A9!5R(E(H5,W#,N_!ZG.":.VL.TZ[@TI94-X8S6
MLRQV'3J@0I+FDWM=6!U5](`]$H?WVS[J<`[Q<:)YCVUY)B,JXS5G)2L%M,,Q
MG8UL%@@RM#2\6HSL<7#R9'#$'J7/J@!?CAH(]O"2JZ*LMS_@ZQ*$K2,@03LR
MP],,5E8>0'AC,1L)QC1=F!B<H7NZY_13IW4AQFIEG$4?"U3>3C:%7_-"P&20
MCH[+,`S(=VKC:\.&[<`7>N02Y(22<"8T>X."9C>`H;E..!>,:JP5W<5V\;8M
M64\!/3+5K\\"O$5D;N31>8'6EY_;Z\H7Q]4QI]LQUU&MW-`OM=F*?>:/MPD*
MW;JG/,E6,U69Z,RO5FDC%S#-4"J,W*#I,2@`ZE./:41*(")[]4:RGK[%355*
M1W"JC"7["HT/!5([27%QEQ)!F<=!P3ZM,6$W[A_E?M^$=[_-T0?_`,/_`#/W
MXZAD/ZH6+ZC_`$<;](?U0\M/ZQ?T=[?G:<>L]L=O[N<7'>P>Q][+GC4"*[G'
MV"/*#Z*[NX/QCSOUN-LO)/SO/T1J7.T/D<].?Z8_:1^>1^Q%\^3YGY[V/F?X
M?VN,16:OF,M/3LC);T?+<W1&Y;3YE#Z-^83_`!3YGR2_,?P'['W-.-?&RCZO
M]7XD2,/90_[#_0MY;K]*'_)(_0?G_OOF\O%UK,]O+W>G9%A_)/8[7O=&V,1C
MWJ?8Z]GO[^\?G.+Y[(^-T1A'XO\`*_O0!WA]CKO#N[_>]WCQOXG\;FSBK1_+
M1XC['V./ON_[I>[]?W=.+^G^9R\N:+*<E?)\W3'D;YC_`.'7>;ROF.\?[_M\
M4M=H_,?=SYXNK^73\KV]/8R.7ZW1.-J8'Z(C?H/\2:_0/T1\PE]&_P`R_>O,
MY>,&K[6G/^)G^F-@S\,99>[ES1^)4O\`Q#]2/K3+?5+[B/UA_P!Z?]+_`,GC
MRHS;SR]_]S9$9R<RS]W][;&,LY?,5W[/?XR]_3E\Q_(_J[_.?W__`)OC.H^V
MKX^0^'G][HC75?\`PO\`F<GES1KT'WW]GM[WO^5QFN_$3\]E[V?-&"U[W].[
M/N\V>SV0#Y/_`.O;R3=_D_??)]OW^+R>W_S'1EGY:HMK^'_RS/3E^F/6;R1_
ML\O(^^\GYPW?YG[;7BMSX:OZGSY:,_+5%^G^(/D,_<S_`$QOC!?0D3]!_1K'
MZ"^A/Q5'Z)_HW]X_@N7C0+[7O\^<$`R&?EJCHF4?HR)_11^/J?I1^C/Q<WT3
M_/\`]E_!Z\5-]H_$T99^6J+3_9]W[V483-W'^QY]]Y7=WCY?Z_%\?$_C],:Y
M/:/RO-G'J+WA]C?O-Y/?Y`]WN^W[G%*-/Q^;IBQI'R,>1_+2^QSW#Y?E^5^Y
M>Y[?N\4M=@_%S/9RY^F(O,?(YZ>B/,WWOV/.\?*_Q#>3[OM^YKQ?:[9^9[/N
MYZ/[OLB]5?P_E,_?Y#V=O1.,]8U^K)/T;?2#G]&OU9[B^1_2'[Y[W&/5]H?%
M[/\`$ST^CVQLF\QV>;HCKF9OJVQ_0G],-OTS?5OYMS^(_P!,?O7F\_%%F^)_
M$R/R^>7E/9&-6Y_P?\R-8B^2;^SV\D/)\GYX/*\WVO/XW!^:7_4,A^WE[W1L
MC2'YA7]+T?MY:>C9'[$;\T/V#OGA^C?FO+)W_P`-^VTXMJ[7\[ISST^1YXS&
M/B?R.7NYQ]Y/(_\`@[WG\CR.\W]_]E[_`!0YF?G.?IBI[(_)?>CR]O[#_E?M
M0[_._6XM#+^:R'K]6K;&*/A'^F_N\\!?GB_8?_<_)^>[_O?VO'I_XK/RYXLL
M9C^E?=Z(V9QK]62_HX_'WGZ-?JSY1/)_G_[][NG&M>^9.?9][M_H@E9^&.Q]
MW*.__P"K\4Q<.4<#W!^+=_L]W</=[OZW$7FGE&?1MU10/@^[E]V(_,0?;PW$
M_P!GG]1H7]$'V\/QV$^T3_N-_H7\-Z-QOZW^B4_]0[?\3Y;WOA?K?[T:ZC^?
A=^4S_A_%R';\LI1(1]Y^Y_M._C1:=,;'1[O:Z?7TQ__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
